Clinical Trials Browser

Neoplasm, Residual

NCT07483476 2026-03-19

CIRCALL

Not yet recruiting

205 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Not yet recruiting

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT07269067 2025-12-08

DUALFLOW

Not yet recruiting

60 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

Not yet recruiting

200 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06941987 2025-04-24

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

Not yet recruiting

66 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT06854939 2025-03-03

MRDSEEKER

Not yet recruiting

350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06449846 2024-06-10

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Not yet recruiting

152 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Neoplasm, Residual

NCT06287723 2024-03-01

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Not yet recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT05850377 2023-05-09

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Not yet recruiting

90 enrolled

CNS

Brain Neoplasms, Glioma, Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Neoplasm, Residual

Clinical Trials

RT4

CIRCALL

TRACE-BTC

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

DUALFLOW

Risk-adapted Therapeutic Strategy in +1q NDMM

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

MRDSEEKER

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas